{"title":"Pediatric nonmalignant hematology ICU admissions: A 10-year study.","authors":"Madalena Afonso, Beatriz Andrade, Eugénia Matos, Leonor Boto, Cristina Camilo, Francisco Abecasis, Marisa Vieira","doi":"10.1080/08880018.2026.2760363","DOIUrl":"https://doi.org/10.1080/08880018.2026.2760363","url":null,"abstract":"<p><p>Nonmalignant hematological disorders in children may lead to severe complications requiring Pediatric Intensive Care Unit (PICU) admission. Data regarding critically ill patients with these conditions remain limited. This study assesses disease burden, clinical course, and critical care requirements in this population. We conducted a retrospective observational study of pediatric patients with nonmalignant hematological disorders in a level III PICU between 2016 and 2025. Demographics, diagnoses, admission characteristics, supportive therapies, organ dysfunction, infectious complications, and outcomes were analyzed. During the study period, 146 admissions involving 91 patients accounted for 3.9% of all PICU admissions. Median age at admission was 10 years (IQR 6.2-13.4), and 56% of patients were male. SCD was the most frequent underlying diagnosis (47 patients, 51.6%; 70 admissions, 47.9%), followed by BMF syndromes (20 patients, 22%; 47 admissions; 32,2%), predominantly aplastic anemia (AA). Most admissions were planned (<i>n</i> = 92, 63%). Surgical indications accounted for 45.2% of admissions (<i>n</i> = 66), medical causes for 39.7% (<i>n</i> = 58), and procedure-related for 15.1% (<i>n</i> = 22). Among unplanned medical admissions, septic shock was the leading cause of PICU admission (40.8%), followed by pulmonary complications. Infectious episodes occurred in 40 admissions, with microorganisms isolated in 47.5% of cases. Healthcare-associated infections (HAI) occurred in 16.4% of admissions. Unplanned admissions were associated with longer PICU stays. Overall PICU mortality was 6.2%, exceeding predicted mortality (3.4%), with septic shock the leading cause of death. Nonmalignant hematological disorders represent a substantial PICU burden, particularly among SCD and BMF patients. Unplanned admissions carried higher morbidity and mortality, underscoring the need for vigilant monitoring and timely escalation of care.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-15"},"PeriodicalIF":1.4,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tolvaptan in the treatment of SIADH-associated hyponatremia in acute lymphoblastic leukemia and lymphoblastic lymphoma: a retrospective study.","authors":"Aditi Jain, Harsha Prasada Lashkari","doi":"10.1080/08880018.2026.2754751","DOIUrl":"https://doi.org/10.1080/08880018.2026.2754751","url":null,"abstract":"<p><p>Hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a recognized complication of chemotherapy in children. Fluid restriction, the conventional management strategy, is often challenging in pediatric oncology due to competing requirements for hydration and nutritional support. Evidence for the use of tolvaptan in this setting remains limited.This retrospective study evaluated the efficacy and safety of tolvaptan in chemotherapy-associated SIADH. Seventeen patients were included, with eight managed using supportive therapy (January 2021-April 2023) and nine receiving tolvaptan (May 2023-November 2025). The primary outcome was time to serum sodium normalization (≥135 mEq/L). Secondary outcomes included 24-h sodium correction, recurrence, and safety.Tolvaptan resulted in a significant increase in serum sodium at 24 h (mean increase 6.5 mEq/L, <i>p</i> = 0.006) and a markedly shorter median time to normalization compared with conventional management (4 vs 25 days), indicating a clinically meaningful benefit. No serious adverse events or overly rapid correction were observed. Tolvaptan may represent a safe and clinically useful option for managing SIADH in pediatric oncology, particularly when fluid restriction is not feasible.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-10"},"PeriodicalIF":1.4,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From perceived acceptability to clinical utility: methodological considerations in pediatric oncology telemedicine.","authors":"Mediha Akcan, Abdullah Barış Akcan","doi":"10.1080/08880018.2026.2756397","DOIUrl":"https://doi.org/10.1080/08880018.2026.2756397","url":null,"abstract":"<p><p>Telemedicine offers potential benefits in pediatric oncology, but its clinical utility requires careful evaluation beyond perceived acceptability. This letter discusses three methodological considerations arising from the study by Frielitz et al.<sup>1</sup> First, the interpretation of questionnaire-derived composite scores requires caution when the instrument has not undergone formal psychometric validation. Second, child self-reports and caregiver-proxy assessments should be distinguished, particularly when younger children's perspectives are underrepresented. Third, anticipated acceptability should not be equated with clinical effectiveness or safety, especially when perceptions are assessed before implementation in a specific epidemiological context. Future research should evaluate questionnaire measurement properties, analyze child and caregiver perspectives separately, and integrate patient-reported experiences with adequately powered assessments of clinical safety and outcomes. These considerations may strengthen the evidence base for individualized hybrid care models in pediatric oncology.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-3"},"PeriodicalIF":1.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparison of clinical characteristics and outcomes of immune thrombocytopenia in Chinese Han children living at high altitude and sea level.","authors":"Qingning Yin, Shuqin Shan, Wenya Qian, Guanling Wang, Jing Wang, Baoqin Shi, Binfei Hu, Jianhua Feng, Yifen Shi","doi":"10.1080/08880018.2026.2749008","DOIUrl":"10.1080/08880018.2026.2749008","url":null,"abstract":"<p><p>Exposure to high altitude can lead to hypobaric hypoxia, which triggers adaptive hematological responses in humans. We examined clinical variation in pediatric immune thrombocytopenia (ITP) across two attitudinally distinct regions and evaluated the influence of altitude on disease outcomes. The study included 156 Chinese Han children with ITP: 68 in the high-altitude group (ALT, Xining City) and 88 in the sea-level group (SEA, Ningbo City). Children in the ALT group were older and presented with higher bleeding grades compared to those in the SEA group. Multivariate logistic regression showed that older age was associated with a significantly greater risk of a prolonged disease course. In contrast, patients who achieved complete response (CR) within 7 days of treatment, as well as those in the ALT group, were less likely to develop a prolonged course. These findings highlight altitude as a potential modifier of pediatric ITP outcomes and warrant further investigation into the underlying mechanisms.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"477-487"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Coen van de Groep, Merlijn van Hamel, Noa Wijnen, Kim Klein, Bianca F Goemans, Michel Zwaan, Gertjan J L Kaspers
{"title":"Premature treatment cessation in pediatric acute myeloid leukemia due to excessive toxicity: clinical experiences and patient outcomes - a case series.","authors":"Coen van de Groep, Merlijn van Hamel, Noa Wijnen, Kim Klein, Bianca F Goemans, Michel Zwaan, Gertjan J L Kaspers","doi":"10.1080/08880018.2026.2742887","DOIUrl":"10.1080/08880018.2026.2742887","url":null,"abstract":"<p><p>Although survival in pediatric acute myeloid leukemia (AML) has improved over the past decades, intensive chemotherapy may be associated with severe and life-threatening toxicities. This case series describes pediatric AML patients in whom therapy was discontinued due to excessive toxicity. Patients were identified through a national database of two consecutive AML treatment protocols in the Netherlands (2010-2023). Seven patients were included; discontinuation of treatment was because of a severe fungal infection in five out of seven cases. Five out of seven patients had a favorable genetic profile; four harboring <i>RUNX1</i>::<i>RUNX1T1</i> and one with a <i>CEBPA</i>-bZIP mutation. All seven patients remain in continuous complete remission with a median follow-up of 6,7 years. This case series shows that selected children with AML who discontinue chemotherapy early due to treatment-related toxicity may still achieve long-term survival and possibly cure. The high incidence of invasive fungal infections highlights a critical cause of treatment-limiting toxicity. This series could inform clinical practice in future similar cases.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"467-476"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sunil Bhat, Ajmeera A Azeez, Atul Achyutrao Thobbi, Meenakshi Nayanapalli, Niveditha S Reddy, Pooja P Mallya, Shreyas A C, Shobha Badiger
{"title":"Clinical Impact of Busulfan Pharmacokinetic Monitoring in Pediatric Allogeneic Transplants: Perspectives from A Transplant Center in A Low- and Middle- Income Country.","authors":"Sunil Bhat, Ajmeera A Azeez, Atul Achyutrao Thobbi, Meenakshi Nayanapalli, Niveditha S Reddy, Pooja P Mallya, Shreyas A C, Shobha Badiger","doi":"10.1080/08880018.2026.2750856","DOIUrl":"10.1080/08880018.2026.2750856","url":null,"abstract":"<p><p>We evaluated the impact of busulfan pharmacokinetic (Bu‑PK) monitoring on toxicity and outcomes in pediatric patients undergoing busulfan-based myeloablative HSCT for benign (<i>n</i> = 221) and malignant diseases (<i>n</i> = 15) at our center in India (January 2023-December 2025). Bu‑PK using liquid chromatography-tandem mass spectrometry was available to 93 patients whose toxicity and outcomes were compared to 143 patients in whom Bu-PK was not done. Once-daily intravenous busulfan was administered over 3 h. Median busulfan dose administered was 105.3 (IQR 93.2-127.6)% with a wide range of 41.7%-213.1% of the standard weight-based dosing, with no added toxicity in those receiving doses >125% of the weight-based dose. Infections, particularly CMV reactivation, were more frequent in the Bu‑PK group with no increase in mortality. Mixed chimerism was significantly lower in the Bu‑PK group (4.6% vs. 24.1%), with an 84% reduction in odds (OR = 0.16, 95% CI 0.05-0.43, <i>p</i> < 0.001). The implementation of monitoring was crucial for overcoming pharmacokinetic variability, reducing mixed chimerism, while maintaining an acceptable overall toxicity profile in our pediatric cohort.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"502-516"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Avi Leader, Ofir Wolach, Baruch Gavrieli, Sarah Elitzur, Henri M H Spronk, Magdolna Nagy, René van Oerle, Galia Spectre, Shai Shimony, Yakir Moshe, Roaya Mahajna, Liron Martin, Gil Gilad, Oded Gilead, Galia Avrahami, Shai Izraeli, Pia Raanani, Shlomit Barzilai-Birenboim
{"title":"Ex Vivo Thrombin Generation Assessment of Four Anticoagulants in Children with Acute Lymphoblastic Leukemia.","authors":"Avi Leader, Ofir Wolach, Baruch Gavrieli, Sarah Elitzur, Henri M H Spronk, Magdolna Nagy, René van Oerle, Galia Spectre, Shai Shimony, Yakir Moshe, Roaya Mahajna, Liron Martin, Gil Gilad, Oded Gilead, Galia Avrahami, Shai Izraeli, Pia Raanani, Shlomit Barzilai-Birenboim","doi":"10.1080/08880018.2026.2750854","DOIUrl":"10.1080/08880018.2026.2750854","url":null,"abstract":"<p><p>Venous thromboembolic events (VTE) are a serious complication in children with acute lymphoblastic leukemia (ALL). Currently, there is no consensus regarding anticoagulant treatment or prevention in this setting, and the role of direct oral anticoagulants (DOACs) has not been extensively studied. The recent approval of DOACs for the treatment of VTE in children supports their further evaluation in pediatric patients with ALL. We prospectively evaluated the effects of four anticoagulant agents in 67 pediatric patients with ALL, compared with healthy controls, using the global coagulation assay thrombin generation (TG). The first 21 patients formed the calibration cohort, and we performed the primary TG analysis in the subsequent 46 patients. Measurements were performed before and after asparaginase therapy, with and without <i>ex vivo</i> spiking of the different anticoagulants. Low-molecular-weight heparin demonstrated preserved anticoagulant activity both before and after asparaginase therapy, with reductions of 29% and 31% in thrombin peak height, respectively, similar to healthy controls. However, the direct factor Xa inhibitors apixaban and rivaroxaban showed minimal anticoagulant effect (7%-13% reduction in thrombin peak height compared with reductions of 48%-59%, in controls). Notably, dabigatran, an oral direct thrombin inhibitor, demonstrated substantial anticoagulant activity before and after asparaginase therapy, with 180% and 134% prolongation of lag time, respectively, comparable to controls. These <i>ex vivo</i> pharmacodynamics findings support the anticoagulant activity of LMWH and dabigatran. The clinical efficacy of dabigatran in pediatric patients with ALL should be further investigated and confirmed in prospective <i>in vivo</i> studies.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"488-501"},"PeriodicalIF":1.4,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149288071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the Editor: Horner Syndrome as a Complication of Neuroblastoma Treatment.","authors":"Burak Ardıçlı, Saniye Ekinci","doi":"10.1080/08880018.2026.2703639","DOIUrl":"10.1080/08880018.2026.2703639","url":null,"abstract":"","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"371-372"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148536558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical and microbiological characteristics of viridans group streptococcal bacteremia in pediatric and adolescent patients with cancer.","authors":"Natsuko Yoshikawa, Suguru Uemura, Shinsuke Mizuno, Saki Tanaka, Natsumi Kikuchi, Nanako Nino, Aiko Kozaki, Atsuro Saito, Toshiaki Ishida, Takeshi Mori, Masashi Kasai, Daiichiro Hasegawa","doi":"10.1080/08880018.2026.2692081","DOIUrl":"10.1080/08880018.2026.2692081","url":null,"abstract":"<p><p>Viridans group streptococci (VGS) are an important cause of bacteremia inpediatric oncology patients and hematopoietic stem cell transplantation (HSCT) recipients, with the potential to viridans streptococcal shock syndrome (VSSS). Increasing β-lactam resistance has raised concerns about the adequacy of current empiric treatment strategies, which typically avoid routine glycopeptide use. We retrospectively analyzed 53 episodes of VGS bacteremia (VGSB) in 42 pediatric and adolescent patients who underwent chemotherapy or HSCT at Kobe Children's Hospital from May 2016 to August 2024. Clinical characteristics, antimicrobial susceptibility, inflammatory markers, and recurrence patterns were assessed. Acute myeloid leukemia (AML) accounted for 49% of episodes, and 60% occurred during cytarabine-containing chemotherapy. Seven patients experienced repeated episodes of VGSB-all with AML; among them, five developed cefepime resistance, and three showed a transition from susceptible to intermediate or resistant isolates during subsequent episodes. Cefepime susceptibility was 64%, whereas all isolates remained susceptible to vancomycin. Exposure to prophylactic antibiotics was significantly associated with the isolation of cefepime-intermediate or resistant strains (10/19 vs. 9/36, <i>p</i> = 0.03). Routine glycopeptide prophylaxis is not justified; however, our findings suggest that AML patients with recurrent VGSB or prior cefepime-nonsusceptible VGS may represent a high-risk subgroup for cefepime-nonsusceptible VGS infection. Further studies are needed to validate risk-adapted antimicrobial strategies in this population.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"307-318"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neuromuscular Changes During the Six-Minute Walk Test in Pediatric Sickle Cell Disease.","authors":"Victoria G Marchese, Simon K Ho, Vicki L Gray","doi":"10.1080/08880018.2026.2694449","DOIUrl":"10.1080/08880018.2026.2694449","url":null,"abstract":"<p><p>Children/adolescents with sickle cell disease (SCD) experience muscle-related impairments and declines in physical function. These deficits result from chronic anemia and impaired oxygen delivery, limiting the development of safe and effective exercise-based interventions. To better understand the effects of SCD on sustained activity, this study aimed to compare the physical function of children/adolescents with SCD to normative values and evaluate changes in neuromuscular function and muscle oxygenation during the 6-min walk test (6MWT). Each child/adolescent underwent a standardized 6MWT while measuring vastus lateralis muscle activity and oxygenation using surface electromyography (EMG) and Near-infrared spectroscopy. Heart rate was also continuously monitored. Compared to age- and sex-matched norms (625.9 ± 55.1 m), children/adolescents with SCD had a higher resting heart rate (108.5 ± 11.7 vs. 90.3 ± 5.0 bpm; <i>p</i> = 0.023), covered less distance (482.7 ± 91.9 m; <i>p</i> = 0.002), but no difference in heart rate at the End of the 6MWT (<i>p</i> = 1.0). Heart rate rose steadily throughout the 6MWT, 121.3 ± 11.1 bpm at the Start (<i>p</i> = 0.17), 139.0 ± 20.3 bpm at Mid (<i>p</i> = 0.009), and 142.1 ± 24.2 bpm at the End (<i>p =</i> 0.009). EMG median frequency decreased significantly from pre-start (82.7 ± 11.7 Hz) to the Start of walking (68.5 ± 21.7 Hz; <i>p</i> = 0.028), and remained low at Mid (68.0 ± 22.4 Hz; <i>p</i> = 0.047) and End (65.7 ± 21.5 Hz; <i>p</i> = 0.047). Children/adolescents with SCD had reduced functional walking capacity, with an elevated resting heart rate and expected increases, sustained changes in neuromuscular activation during submaximal, sustained activities. This suggests that routine activities may place greater physiologic demands on children/adolescents with SCD, and that clinical assessments may require more than just walking distance.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"319-329"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}